Aug 03, 2025
Metabolic stability assay in human, rat, dog or mouse hepatocytes
- Nick Lynch1,2
- 1Curlew Research;
- 2ASAP Discovery Consortium
- ASAP Discovery
Protocol Citation: Nick Lynch 2025. Metabolic stability assay in human, rat, dog or mouse hepatocytes . protocols.io https://dx.doi.org/10.17504/protocols.io.14egnykbqv5d/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: May 25, 2025
Last Modified: August 03, 2025
Protocol Integer ID: 218899
Keywords: metabolic stability, hepatocyte, ADME, DMPK, drug discovery, understanding metabolic stability, metabolic stability, drug development, hepatocyte, liver cell, drug compound, critical aspect of drug discovery, stability, drug discovery, liver, drug, assay, identifying compound
Disclaimer
The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgement, advice, diagnosis, or treatment. Any action you take or refrain from taking, using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held
Abstract
Metabolic stability, measured in hepatocytes, refers to the rate at which a drug compound is metabolized or broken down by liver cells. This is a critical aspect of drug discovery and development, as it helps determine how long a drug will remain in the body and at what concentration it will exert its therapeutic effect. In drug development, understanding metabolic stability is crucial for identifying compounds that are stable enough to reach their target and for optimizing chemical structures to improve metabolic stability.
Troubleshooting
Safety warnings
Always wear appropriate PPE for this protocol
Refer to Material Safety Data Sheets for additional safety and handling information.
Summary
The metabolic stability in the hepatocytes is performed in 96-well plate format
This protocol can be used with the following hepatocytes:
- Human
- Rat
- Mouse
- Dog
Sample Preparation
The compounds are incubated in 1 uM concentration in a shaking incubator at 37ºC
The relevant hepatocytes are diluted to a concentration of 0.5x10^6 cells /mL and equilibrated at 37ºC for 10 minutes
Assay
Biotransformation is initiated by addition of compound and mixing
Standard time-points are used as 0, 5, 10, 20, 40, 60 min, and the final solvent concentrations are 0.99 % methanol and 0.01 % DMSO
At each specified time-point, a sample aliquot (25μL) is removed from the test incubation mixture and combined into a cassette of up to 4 compounds, in 300μL ice cold methanol containing internal standards (Dextromethorphan, Diazepam, Midazolam, Phenacetin and Naloxone), and mixing to stop the reaction
The quenched samples are then centrifuged to precipitate the protein.
Analytical
The supernatants are analyzed by LC-MS/MS using generic analytical methods to measure the test parent compound remaining at each time-point.
Data Analysis
Clearance and half-life are calculated from the elimination rate constant derived from plotting response ratio versus time
For each test compound injection,
Response rate = Test peak area / Internal standard peak area
The natural log of the test compound response ratio is plotted versus time.
The -ve slope of the semilog plot gives the elimination rate constant k (min-1), from which intrinsic clearance Clint (μL/min/106 cells) and half-life t1/2 (min) are calculated.
E.g. t1/2 (min) = Ln2 / k(min-1)
Acknowledgements
Grateful to Concept Life Sciences for supplying the original protocol summary